GlassScriptPhysician profile
Eduardo D Flores
NPI 1528062973
$7,949.26
in general payments reported to CMS, 2019-2025
28 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,927 · 2020: $810 · 2021: $1,008 · 2022: $1,245 · 2023: $847 · 2024: $917 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.61 |
| Education | $143.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,154.01 | 2019-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $1,103.58 | 2019-2025 | Gallant, Jot Dx, Merlin@Home |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $681.43 | 2019-2025 | Lifevest |
| Medtronic, INC. | $651.26 | 2021-2025 | Corevalve Evolut R, Cg Future |
| Abiomed | $596.91 | 2020-2025 | Impella |
| Janssen Pharmaceuticals, INC | $557.84 | 2019-2020 | |
| Shockwave Medical, INC | $384.52 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $355.60 | 2020-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $272.03 | 2019-2025 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $265.26 | 2019-2025 | |
| Pfizer INC. | $251.16 | 2019-2021 | |
| Medtronic Vascular, INC. | $232.56 | 2019-2020 | |
| Inari Medical, INC. | $192.61 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $167.96 | 2020-2024 | Avvigo Guidance System |
| Amgen INC. | $161.11 | 2019-2025 | Repatha, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $149.00 | 2024 | Acticor 7 Vr-T Dx, Biomonitor, Renamic Neo |
| Impulse Dynamics (USA) INC. | $136.06 | 2025 | Optimizer |
| Novo Nordisk INC | $130.58 | 2022-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $117.40 | 2019 | |
| Amarin Pharma, INC. | $103.54 | 2019-2020 | |
| Ekos Corporation | $79.83 | 2019 | |
| Gilead Sciences, INC. | $51.26 | 2019 | |
| Silk Road Medical, INC. | $47.61 | 2020-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.91 | 2024 | Jardiance |
| Teleflex LLC | $20.13 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2019 | |
| Atricure, INC. | $17.38 | 2025 | Atricure Cryoice Cryoablation System (Cryo2) |
| Heartflow, INC. | $14.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.